Structure Therapeutics recently reported strong Phase 2b results for its oral weight-loss candidate aleniglipron, secured a ...
Structure Therapeutics (GPCR) has been in focus after reporting positive phase 2 results for its oral weight loss candidate ...
Stocktwits on MSN
VKTX, TERN, GPCR shares rally as Novo Nordisk sounds willingness towards portfolio-expansion deals
Viking CEO Brian Lian said at the conference earlier this week that the strategic interest in weight-loss drug deals is ...
Fintel on MSN
Structure Therapeutics Inc. - Depositary Receipt (GPCR) price target increased by 10.08% to 103.82
The average one-year price target for Structure Therapeutics Inc. - Depositary Receipt (NasdaqGM:GPCR) has been revised to ...
As of Tuesday, January 13, Structure Therapeutics Inc.’s GPCR share price has surged by 6.29%, which has investors ...
Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies -- Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of ...
The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...
Domain Therapeutics becomes Kainova Therapeutics and advances its clinical pipeline of GPCR-modulating therapies: Montreal, Canada Tuesday, January 13, 2026, 18:00 Hrs [IST] Kaino ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback